



Verici Dx plc
("Verici Dx" or the "Company")

ISO 27001 Information Security Certification Achieved

Verici Dx, a developer of advanced clinical diagnostics for organ transplant, announces that it has attained the ISO 27001 certification for its Information Security Management System ("ISMS").

ISO 27001 is an international standard specifying requirements for an ISMS, and conformity with the standard means that Verici Dx's system meets world-wide best practice with regards to managing risks related to the security of data owned or handled by the Company.

This certification underlines Verici Dx's commitment to implementing comprehensive security measures, ensuring the protection of sensitive data and information, and reinforces the Company's position as a trusted partner in industry and within patient care. With this certification, Verici Dx is well-equipped to continue delivering innovative diagnostic solutions while ensuring the highest level of protection for all sensitive information.

Dave Schultenover, VP Quality and Regulatory Affairs at Verici Dx, said: *"We are pleased to have achieved the ISO 27001 certification, which underscores our unwavering commitment to maintaining the utmost security and confidentiality of data within our operations."*

Patti Connolly, Chief Operating Officer at Verici Dx, added: *"Achieving this international standard is testament to the quality of the Verici Dx team, and the robustness of our systems and processes that maintain the highest level of data protection for patients, clients, partners, and stakeholders."*

Enquiries:

Verici Dx
Sara Barrington, CEO
Julian Baines, Chairman

www.vericidx.com
Via Walbrook PR

Singer Capital Markets (Nominated Adviser & Broker)
Aubrey Powell / Sam Butcher / Jalini Kalaravy

Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus / Stephanie Cuthbert / Sam Allen

Tel: 020 7933 8780 or vericidx@walbrookpr.com
Mob: 07980 541 893 / 07502 558 258

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAMZMZRNGFZZ